medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-7-26-33medalphabet-3673Research ArticleДИАГНОСТИКА И ОНКОТЕРАПИЯDIAGNOSTICS AND ONCOTHERAPYКардиотоксичность ингибиторов контрольных точек: фокус на иммунных побочных эффектахCardiotoxicity of checkpoint inhibitors: focus on immune side effectshttps://orcid.org/0000-0001-7016-7541БузиашвилиЮ. И.BuziashviliJu. I.

Бузиашвили Юрий Иосифович - д.м.н., профессор, академик РАН, зав. клинико-диагностическим отделением

Москва

Buziashvili Jurij I. - DM Sci (habil.), professor, academician of the Russian Academy of Sciences, head of Clinico-Diagnostic Dept

Moscow

https://orcid.org/0000-0002-5422-2069АсымбековаЭ. У.AsymbekovaE. U.

Асымбекова Эльмира Уметовна - д.м.н., в.н.с. клинико-диагностического отделения

Москва

Asymbekova El’mira U. - DM Sci (habil.), leading researcher at Clinico-Diagnostic Dept

Moscow

https://orcid.org/0000-0003-1751-4924ТугееваЭ. Ф.TugeevaE. F.

Тугеева Эльвина Фаатовна - д.м.н., с.н.с. клинико-диагностического отделения

Москва

Tugeeva Elvina Faatovna - DM Sci (habil.), senior researcher at Clinico-Diagnostic Dept

Moscow

https://orcid.org/0000-0002-8936-3590АртамоноваЕ. В.ArtamonovaE. V.

Артамонова Елена Владимировна - д.м.н., в.н.с. отделения изучения новых противоопухолевых лекарств

Москва

Artamonova Elena V. - DM Sci (habil.), leading researcher at Dept for the Study of New Anticancer Drugs

Moscow

https://orcid.org/0000-0002-1675-4216АкилджоновФ. Р.AkildzhonovF. R.

Акилджонов Фирдавсджон Рустамджонович - аспирант клинико-диагностического отделения

Москва

Akildzhonov Firdavsdzhon R. - postgraduate at Clinico-Diagnostic Dept

Moscow

firdavs96_tths@mail.ruФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева»РоссияBakoulev National Medical Research Center for Cardiovascular SurgeryRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина»РоссияN.N. Blokhin Russian Cancer Research CenterRussian Federation20240905202407«Диагностика и онкотерапия» (1)2633Copyright © Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф., Артамонова Е.В., Акилджонов Ф.Р., 20242024Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф., Артамонова Е.В., Акилджонов Ф.Р.Buziashvili J.I., Asymbekova E.U., Tugeeva E.F., Artamonova E.V., Akildzhonov F.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3673

Показания к применению ингибиторов контрольных точек при онкологических заболеваниях продолжает расширяться в ближайшие годы, что является перспективным направлением для будущих клинических исследований. Однако диагностика иммунных побочных эффектов является сложной задачей из-за его гетерогенных клинических проявлений, которые варьируются от субклинического течения до молниеносных проявлений с высокой госпитальной летальностью. Потенциальным механизмом может быть пролиферация и клональная экспансия Т-лимфоцитами антигенов в опухолевых клетках и пораженных собственных тканях. Точный патофизиологический механизм остается неясным, а профиль риска пациентов, столкнувшихся с кардиотоксичностью, неизвестен. Продолжающиеся интенсивные усилия исследовательских сообществ и междисциплинарное сотрудничество в области онкологии и кардиологии помогут решить эти проблемы и тем самым позволят иммунотерапии достичь максимального потенциального эффекта в лечении онкологических заболеваний.

The indications for the use of checkpoint inhibitors in cancer diseases continue to expand in the coming years, which is a promising area for future clinical research. However, diagnosis of immune-related side effects is challenging due to its heterogeneous clinical manifestations, which range from subclinical to fulminant manifestations with high in-hospital mortality. A potential mechanism may be proliferation and clonal expansion of antigens by T-lymphocytes in tumor cells and affected self-tissues. The exact pathophysiological mechanism remains unclear and the risk profile of patients experiencing cardiotoxicity is unknown. Continued intensive efforts by the research communities and interdisciplinary collaborations in oncology and cardiology will help address these challenges and thereby allow immunotherapy to achieve its maximum potential benefit in the treatment of cancer

кардиотоксичностьиммунотерапияингибиторы контрольных точекcardiotoxicityimmunotherapyimmune checkpoint inhibitorsReferencesXiang Y, Gong M, Deng Y, Wang H, Ye D. T cell effects and mechanisms in immunotherapy of head and neck tumors. Cell Commun Signal. 2023;21(1):49. Published 2023 Mar 5. doi:10.1186/s12964–023–01070-yXiang Y, Gong M, Deng Y, Wang H, Ye D. T cell effects and mechanisms in immunotherapy of head and neck tumors. Cell Commun Signal. 2023;21(1):49. Published 2023 Mar 5. doi:10.1186/s12964–023–01070-yBuchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239L’Orphelin JM, Varey E, Khammari A, Dreno B, Dompmartin A. Severe Late-Onset Grade III–IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers (Basel). 2021;13(19):4928. Published 2021 Sep 30. doi:10.3390/ cancers13194928L’Orphelin JM, Varey E, Khammari A, Dreno B, Dompmartin A. Severe Late-Onset Grade III–IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers (Basel). 2021;13(19):4928. Published 2021 Sep 30. doi:10.3390/ cancers13194928L’Orphelin JM, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers (Basel). 2023;15(7):2170. Published 2023 Apr 6. doi:10.3390/cancers15072170L’Orphelin JM, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers (Basel). 2023;15(7):2170. Published 2023 Apr 6. doi:10.3390/cancers15072170Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combi-nation Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combi-nation Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214Frascaro F, Bianchi N, Sanguettoli F, et al. Immune Checkpoint Inhibitors-Asso-ciated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J Clin Med. 2023;12(24):7737. Published 2023 Dec 17. doi:10.3390/jcm12247737Frascaro F, Bianchi N, Sanguettoli F, et al. Immune Checkpoint Inhibitors-Asso-ciated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J Clin Med. 2023;12(24):7737. Published 2023 Dec 17. doi:10.3390/jcm12247737Bi H, Ren D, Wang Q, Ding X, Wang H. Immune checkpoint inhibitor-induced myo-carditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Ann Palliat Med. 2021;10(1):793–802. doi:10.21037/apm-20–2449Bi H, Ren D, Wang Q, Ding X, Wang H. Immune checkpoint inhibitor-induced myo-carditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Ann Palliat Med. 2021;10(1):793–802. doi:10.21037/apm-20–2449Wong CK, Lam TH, Liao SY, Lau YM, Tse HF, So BYF. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. Biomedicines. 2023;11(1):107. Published 2023 Jan 1. doi:10.3390/biomedicines11010107Wong CK, Lam TH, Liao SY, Lau YM, Tse HF, So BYF. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. Biomedicines. 2023;11(1):107. Published 2023 Jan 1. doi:10.3390/biomedicines11010107Chiang CH, Chiang CH, Ma KS, et al. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol. 2022;52(12):1389–1398. doi:10.1093/jjco/hyac150Chiang CH, Chiang CH, Ma KS, et al. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol. 2022;52(12):1389–1398. doi:10.1093/jjco/hyac150Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week [published correction appears in J Am Coll Cardiol. 2019 Nov 26;74(21):2711–2712]. J Am Coll Cardiol. 2019;74(13):1714–1727. doi:10.1016/j.jacc.2019.07.079Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week [published correction appears in J Am Coll Cardiol. 2019 Nov 26;74(21):2711–2712]. J Am Coll Cardiol. 2019;74(13):1714–1727. doi:10.1016/j.jacc.2019.07.079Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830. doi:10.1007/s10147–019–01548–1Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830. doi:10.1007/s10147–019–01548–1Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044–3060. Published 2022 Apr 24. doi:10.3390/curroncol29050247Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044–3060. Published 2022 Apr 24. doi:10.3390/curroncol29050247Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother. 2016;12(5):1092–1101. doi:10.1080/21645515.2015.1129478Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother. 2016;12(5):1092–1101. doi:10.1080/21645515.2015.1129478Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T. 2017;42(8):514–521.Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T. 2017;42(8):514–521.Eno J. Immunotherapy Through the Years. J Adv Pract Oncol. 2017;8(7):747–753.Eno J. Immunotherapy Through the Years. J Adv Pract Oncol. 2017;8(7):747–753.Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. Published 2020 Apr 3. doi:10.1186/s13045–020–00862-wPan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. Published 2020 Apr 3. doi:10.1186/s13045–020–00862-wParvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Im-munol. 2023;14:1296341. Published 2023 Dec 1. doi:10.3389/fimmu.2023.1296341Parvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Im-munol. 2023;14:1296341. Published 2023 Dec 1. doi:10.3389/fimmu.2023.1296341Xu Y, Wan B, Chen X, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8(4):413–428. doi:10.21037/tlcr.2019.08.09Xu Y, Wan B, Chen X, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8(4):413–428. doi:10.21037/tlcr.2019.08.09Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol. 2023;29(6):1054–1075. doi:10.3748/wjg.v29.i6.1054Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol. 2023;29(6):1054–1075. doi:10.3748/wjg.v29.i6.1054Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel). 2023;15(4):1106. Published 2023 Feb 9. doi:10.3390/cancers15041106Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel). 2023;15(4):1106. Published 2023 Feb 9. doi:10.3390/cancers15041106Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: un-derstanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423–020–0488–6Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: un-derstanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423–020–0488–6Eskandari-Malayeri F, Rezaei M. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Front Immunol. 2022;13:996145. Published 2022 Oct 5. doi:10.3389/fimmu.2022.996145Eskandari-Malayeri F, Rezaei M. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Front Immunol. 2022;13:996145. Published 2022 Oct 5. doi:10.3389/fimmu.2022.996145Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer. 2021;12(4):1133–1143. Published 2021 Jan 1. doi:10.7150/jca.49325Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer. 2021;12(4):1133–1143. Published 2021 Jan 1. doi:10.7150/jca.49325Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20(4):265–271. doi:10.1097/PPO.0000000000000059Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20(4):265–271. doi:10.1097/PPO.0000000000000059Paucek RD, Baltimore D, Li G. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends Immunol. 2019;40(4):292–309. doi:10.1016/j.it.2019.02.002Paucek RD, Baltimore D, Li G. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends Immunol. 2019;40(4):292–309. doi:10.1016/j.it.2019.02.002Liu H, Zhao Y, Xie A, et al. Interleukin-1β, Oxidative Stress, and Abnormal Calcium Handling Mediate Diabetic Arrhythmic Risk. JACC Basic Transl Sci. 2021;6(1):42–52. Published 2021 Jan 20. doi:10.1016/j.jacbts.2020.11.002Liu H, Zhao Y, Xie A, et al. Interleukin-1β, Oxidative Stress, and Abnormal Calcium Handling Mediate Diabetic Arrhythmic Risk. JACC Basic Transl Sci. 2021;6(1):42–52. Published 2021 Jan 20. doi:10.1016/j.jacbts.2020.11.002Cone EB, Haeuser L, Reese SW, et al. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS One. 2022;17(11): e0272022. Published 2022 Nov 1. doi:10.1371/journal.pone.0272022Cone EB, Haeuser L, Reese SW, et al. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS One. 2022;17(11): e0272022. Published 2022 Nov 1. doi:10.1371/journal.pone.0272022Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. Published 2021 Oct 18. doi:10.3390/cancers13205218Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. Published 2021 Oct 18. doi:10.3390/cancers13205218Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv Pharmacol. 2022;94:365–409. doi:10.1016/bs.apha.2022.02.002Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv Pharmacol. 2022;94:365–409. doi:10.1016/bs.apha.2022.02.002Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. doi:10.1007/s11936–020–00867–1Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. doi:10.1007/s11936–020–00867–1Baik AH, Oluwole OO, Johnson DB, et al. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021;128(11):1780–1801. doi:10.1161/CIRCRESAHA.120.315894Baik AH, Oluwole OO, Johnson DB, et al. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021;128(11):1780–1801. doi:10.1161/CIRCRESAHA.120.315894Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019;6(2):19. Published 2019 Apr 27. doi:10.3390/jcdd6020019Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019;6(2):19. Published 2019 Apr 27. doi:10.3390/jcdd6020019Waheed N, Fradley MG, DeRemer DL, et al. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021;7(1):10. Published 2021 Mar 18. doi:10.1186/s40959–021–00097–9Waheed N, Fradley MG, DeRemer DL, et al. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021;7(1):10. Published 2021 Mar 18. doi:10.1186/s40959–021–00097–9Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol. 2022;13:835510. Published 2022 Apr 19. doi:10.3389/fphar.2022.835510Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol. 2022;13:835510. Published 2022 Apr 19. doi:10.3389/fphar.2022.835510Ito T, Kaku-Ito Y, Ohno F, Nakahara T. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan. Front Med (Lausanne). 2023;10:1293397. Published 2023 Dec 7. doi:10.3389/fmed.2023.1293397Ito T, Kaku-Ito Y, Ohno F, Nakahara T. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan. Front Med (Lausanne). 2023;10:1293397. Published 2023 Dec 7. doi:10.3389/fmed.2023.1293397Chitturi KR, Xu J, Araujo-Gutierrez R, et al. Immune Checkpoint Inhibitor-Re-lated Adverse Cardiovascular Events in Patients With Lung Cancer. JACC CardioOncol. 2019;1(2):182–192. Published 2019 Dec 17. doi:10.1016/j.jac-cao.2019.11.013Chitturi KR, Xu J, Araujo-Gutierrez R, et al. Immune Checkpoint Inhibitor-Re-lated Adverse Cardiovascular Events in Patients With Lung Cancer. JACC CardioOncol. 2019;1(2):182–192. Published 2019 Dec 17. doi:10.1016/j.jac-cao.2019.11.013Zhao F, Shen D, Shang M, et al. Immunotherapy: A new target for cancer cure (Review). Oncol Rep. 2023;49(5):100. doi:10.3892/or.2023.8537Zhao F, Shen D, Shang M, et al. Immunotherapy: A new target for cancer cure (Review). Oncol Rep. 2023;49(5):100. doi:10.3892/or.2023.8537Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, Shah ND, Riaz IB, Mansfield AS. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clin Lung Cancer. 2020;21(5):421–427.e2. doi:10.1016/j.cllc.2020.04.003Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, Shah ND, Riaz IB, Mansfield AS. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clin Lung Cancer. 2020;21(5):421–427.e2. doi:10.1016/j.cllc.2020.04.003Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Mag-netic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myo-carditis. J Am Coll Cardiol. 2021;77(12):1503–1516. doi:10.1016/j.jacc.2021.01.050Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Mag-netic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myo-carditis. J Am Coll Cardiol. 2021;77(12):1503–1516. doi:10.1016/j.jacc.2021.01.050Zotova L. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Re-ported Clinical Cases. Diagnostics (Basel). 2023;13(7):1243. Published 2023 Mar 25. doi:10.3390/diagnostics13071243Zotova L. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Re-ported Clinical Cases. Diagnostics (Basel). 2023;13(7):1243. Published 2023 Mar 25. doi:10.3390/diagnostics13071243Bockstahler M, Fischer A, Goetzke CC, et al. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immuno-proteasome Inhibitor and Genetic Ablation. Circulation. 2020;141(23):1885–1902. doi:10.1161/CIRCULATIONAHA.119.043171Bockstahler M, Fischer A, Goetzke CC, et al. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immuno-proteasome Inhibitor and Genetic Ablation. Circulation. 2020;141(23):1885–1902. doi:10.1161/CIRCULATIONAHA.119.043171Trontzas IP, Vathiotis IA, Kyriakoulis KG, et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. Published 2023 May 6. doi:10.3390/cancers15092637Trontzas IP, Vathiotis IA, Kyriakoulis KG, et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. Published 2023 May 6. doi:10.3390/cancers15092637Verbeek JS, Hirose S, Nishimura H. The Complex Association of FcγRIIb With Autoimmune Susceptibility. Front Immunol. 2019;10:2061. Published 2019 Oct 15. doi:10.3389/fimmu.2019.02061Verbeek JS, Hirose S, Nishimura H. The Complex Association of FcγRIIb With Autoimmune Susceptibility. Front Immunol. 2019;10:2061. Published 2019 Oct 15. doi:10.3389/fimmu.2019.02061Miyabe C, Dong Y, Ikeda T, Takahashi K, Miyabe Y, Kawakami T. Immune check-point molecule expression is altered in the skin and peripheral blood in vasculitis. Sci Rep. 2021;11(1):20019. Published 2021 Oct 8. doi:10.1038/s41598–021–99558–5Miyabe C, Dong Y, Ikeda T, Takahashi K, Miyabe Y, Kawakami T. Immune check-point molecule expression is altered in the skin and peripheral blood in vasculitis. Sci Rep. 2021;11(1):20019. Published 2021 Oct 8. doi:10.1038/s41598–021–99558–5Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-on-cology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023 May 7;44(18):1621]. Eur Heart J. 2022;43(41):4229–4361. doi:10.1093/eurheartj/ehac244Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-on-cology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023 May 7;44(18):1621]. Eur Heart J. 2022;43(41):4229–4361. doi:10.1093/eurheartj/ehac244Teymouri N, Mesbah S, Navabian SMH, et al. ECG frequency changes in po-tassium disorders: a narrative review. Am J Cardiovasc Dis. 2022;12(3):112–124. Published 2022 Jun 15.Teymouri N, Mesbah S, Navabian SMH, et al. ECG frequency changes in po-tassium disorders: a narrative review. Am J Cardiovasc Dis. 2022;12(3):112–124. Published 2022 Jun 15.Ganesh S, Zhong P, Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treat-ment. Front Cardiovasc Med. 2022;9:997660. Published 2022 Sep 20. doi:10.3389/ fcvm.2022.997660Ganesh S, Zhong P, Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treat-ment. Front Cardiovasc Med. 2022;9:997660. Published 2022 Sep 20. doi:10.3389/ fcvm.2022.997660Zhao Y, Lyu N, Zhang W, Tan H, Jin Q, Dang A. Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis. Front Car-diovasc Med. 2022;9:839763. Published 2022 Mar 30. doi:10.3389/fcvm.2022.839763Zhao Y, Lyu N, Zhang W, Tan H, Jin Q, Dang A. Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis. Front Car-diovasc Med. 2022;9:839763. Published 2022 Mar 30. doi:10.3389/fcvm.2022.839763Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The Role of Speckle Strain Echocardiography in the Diagnosis of Early Subclinical Cardiac Injury in Cancer Patients-Is There More Than Just Left Ventricle Global Longitudinal Strain?. J Clin Med. 2021;10(1):154. Published 2021 Jan 5. doi:10.3390/jcm10010154Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The Role of Speckle Strain Echocardiography in the Diagnosis of Early Subclinical Cardiac Injury in Cancer Patients-Is There More Than Just Left Ventricle Global Longitudinal Strain?. J Clin Med. 2021;10(1):154. Published 2021 Jan 5. doi:10.3390/jcm10010154Cadour F, Cautela J, Rapacchi S, et al. Cardiac MRI Features and Prognos-tic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022;303(3):512–521. doi:10.1148/radiol.211765Cadour F, Cautela J, Rapacchi S, et al. Cardiac MRI Features and Prognos-tic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022;303(3):512–521. doi:10.1148/radiol.211765Ammirati E, Buono A, Moroni F, et al. State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597–609. doi:10.1007/s11886–022–01680-xAmmirati E, Buono A, Moroni F, et al. State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597–609. doi:10.1007/s11886–022–01680-xBonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Ther-apeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-On-cology. Circulation. 2019;140(2):80–91. doi:10.1161/CIRCULATIONAHA.118.034497Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Ther-apeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-On-cology. Circulation. 2019;140(2):80–91. doi:10.1161/CIRCULATIONAHA.118.034497Bai X, Hu J, Betof Warner A, et al. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021;27(21):5993–6000. doi:10.1158/1078–0432.CCR-21–1283Bai X, Hu J, Betof Warner A, et al. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021;27(21):5993–6000. doi:10.1158/1078–0432.CCR-21–1283Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept [published correction appears in J Immunother Cancer. 2022 May;10(5):]. J Immunother Cancer. 2022;10(4): e004699. doi:10.1136/jitc-2022–004699Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept [published correction appears in J Immunother Cancer. 2022 May;10(5):]. J Immunother Cancer. 2022;10(4): e004699. doi:10.1136/jitc-2022–004699Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the man-agement of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol. 2020;16(4):201–210. doi:10.1111/ajco.13332Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the man-agement of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol. 2020;16(4):201–210. doi:10.1111/ajco.13332

The authors declare that there are no conflicts of interest present.